Brain Cancer Clinical Trial
Official title:
Study of Clinical Biomarkers in Human Health and Disease (Healthiomics)
Verified date | August 2023 |
Source | CureScience |
Contact | Amanda Wilburn |
Phone | 8588002873 |
awilburn[@]curescience.orgg | |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to collect clinical data, biological specimens (e.g., blood, tumor, cerebrospinal fluid, urine sample, etc.), and digital health data from patients with tumors, cancer and/or neurological disorders in order to perform research studies that could advance patient care. By collecting these specimens, the investigators plan to create and maintain a biorepository to make data and specimens available to collaborating investigators performing research to discover predictive biomarkers, patterns of care, and personalized treatments that could directly improve the care of our patients through focused proof-of-concept clinical trials.
Status | Recruiting |
Enrollment | 3500 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participant or participant's legally authorized representative has the ability to understand and the willingness to provide a signed and dated informed consent form. - Participant is = 18 years of age. - Participant had/has a scheduled appointment with oncology or neurosciences services at the participating medical and surgical facility. - Participant is characterized by at least one of the following criteria: 1. Has a neurological complication from any type of cancer, or is under evaluation for a possible cancer diagnosis or neurologic complication. Participant may be newly diagnosed, in relapse, or be free of disease at the time of recruitment. Participant without a confirmed cancer diagnosis is eligible.; OR 2. Has a neurological disorder, or is under evaluation for a possible diagnosis of a neurological disorder; OR 3. Does not meet the characteristic of either a. or b. above. This participant would be considered a "healthy control" for cancer and neurological disorders. Exclusion Criteria: - Participant or participant's legally authorized representative is unable to provide informed consent. |
Country | Name | City | State |
---|---|---|---|
United States | CureScience Institute | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
CureScience |
United States,
Bent B, Goldstein BA, Kibbe WA, Dunn JP. Investigating sources of inaccuracy in wearable optical heart rate sensors. NPJ Digit Med. 2020 Feb 10;3:18. doi: 10.1038/s41746-020-0226-6. eCollection 2020. — View Citation
Braun KL, Tsark JU, Powers A, Croom K, Kim R, Gachupin FC, Morris P. Cancer patient perceptions about biobanking and preferred timing of consent. Biopreserv Biobank. 2014 Apr;12(2):106-12. doi: 10.1089/bio.2013.0083. — View Citation
Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007 Sep;48(9):1468-81. doi: 10.2967/jnumed.106.037689. Epub 2007 Aug 17. — View Citation
Fulham MJ, Bizzi A, Dietz MJ, Shih HH, Raman R, Sobering GS, Frank JA, Dwyer AJ, Alger JR, Di Chiro G. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology. 1992 Dec;185(3):675-86. doi: 10.1148/radiology.185.3.1438744. — View Citation
Gillinov S, Etiwy M, Wang R, Blackburn G, Phelan D, Gillinov AM, Houghtaling P, Javadikasgari H, Desai MY. Variable Accuracy of Wearable Heart Rate Monitors during Aerobic Exercise. Med Sci Sports Exerc. 2017 Aug;49(8):1697-1703. doi: 10.1249/MSS.0000000000001284. — View Citation
Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol. 2006;10(A):133-146. — View Citation
Hawighorst H, Knopp MV, Debus J, Hoffmann U, Grandy M, Griebel J, Zuna I, Essig M, Schoenberg SO, DeVries A, Brix G, van Kaick G. Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: initial results. J Magn Reson Imaging. 1998 Jul-Aug;8(4):783-8. doi: 10.1002/jmri.1880080406. — View Citation
Heesters MA, Kamman RL, Mooyaart EL, Go KG. Localized proton spectroscopy of inoperable brain gliomas. Response to radiation therapy. J Neurooncol. 1993 Jul;17(1):27-35. doi: 10.1007/BF01054271. — View Citation
Helfer JL, Wen PY, Blakeley J, Gilbert MR, Armstrong TS. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). Neuro Oncol. 2016 Mar;18 Suppl 2(Suppl 2):ii26-ii36. doi: 10.1093/neuonc/nov270. — View Citation
Hewitt R, Watson PH, Dhir R, Aamodt R, Thomas G, Mercola D, Grizzle WE, Morente MM. Timing of consent for the research use of surgically removed tissue: is postoperative consenting acceptable? Cancer. 2009 Jan 1;115(1):4-9. doi: 10.1002/cncr.23999. No abstract available. — View Citation
Hoskin PJ, Saunders MI, Goodchild K, Powell ME, Taylor NJ, Baddeley H. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol. 1999 Nov;72(863):1093-8. doi: 10.1259/bjr.72.863.10700827. — View Citation
Huhn SL, Mohapatra G, Bollen A, Lamborn K, Prados MD, Feuerstein BG. Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization: correlation with radiation treatment outcome. Clin Cancer Res. 1999 Jun;5(6):1435-43. — View Citation
Huisman TA, Schwamm LH, Schaefer PW, Koroshetz WJ, Shetty-Alva N, Ozsunar Y, Wu O, Sorensen AG. Diffusion tensor imaging as potential biomarker of white matter injury in diffuse axonal injury. AJNR Am J Neuroradiol. 2004 Mar;25(3):370-6. — View Citation
Kmiecik J, Poli A, Brons NH, Waha A, Eide GE, Enger PO, Zimmer J, Chekenya M. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. 2013 Nov 15;264(1-2):71-83. doi: 10.1016/j.jneuroim.2013.08.013. Epub 2013 Aug 31. — View Citation
Lin S, Yu W, Wang B, Zhao Y, En K, Zhu J, Cheng X, Zhou C, Lin H, Wang Z, Hojaiji H, Yeung C, Milla C, Davis RW, Emaminejad S. Noninvasive wearable electroactive pharmaceutical monitoring for personalized therapeutics. Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19017-19025. doi: 10.1073/pnas.2009979117. Epub 2020 Jul 27. — View Citation
Malmberg KJ, Ljunggren HG. Escape from immune- and nonimmune-mediated tumor surveillance. Semin Cancer Biol. 2006 Feb;16(1):16-31. doi: 10.1016/j.semcancer.2005.07.007. Epub 2005 Sep 2. — View Citation
Nelson BW, Allen NB. Accuracy of Consumer Wearable Heart Rate Measurement During an Ecologically Valid 24-Hour Period: Intraindividual Validation Study. JMIR Mhealth Uhealth. 2019 Mar 11;7(3):e10828. doi: 10.2196/10828. — View Citation
Prendergast CT, Anderton SM. Immune cell entry to central nervous system--current understanding and prospective therapeutic targets. Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):315-27. doi: 10.2174/187153009789839219. — View Citation
Schmitt P, Kotas M, Tobermann A, Haase A, Flentje M. Quantitative tissue perfusion measurements in head and neck carcinoma patients before and during radiation therapy with a non-invasive MR imaging spin-labeling technique. Radiother Oncol. 2003 Apr;67(1):27-34. doi: 10.1016/s0167-8140(03)00024-0. — View Citation
Stehlik J, Schmalfuss C, Bozkurt B, Nativi-Nicolau J, Wohlfahrt P, Wegerich S, Rose K, Ray R, Schofield R, Deswal A, Sekaric J, Anand S, Richards D, Hanson H, Pipke M, Pham M. Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization: The LINK-HF Multicenter Study. Circ Heart Fail. 2020 Mar;13(3):e006513. doi: 10.1161/CIRCHEARTFAILURE.119.006513. Epub 2020 Feb 25. — View Citation
Thomson EA, Nuss K, Comstock A, Reinwald S, Blake S, Pimentel RE, Tracy BL, Li K. Heart rate measures from the Apple Watch, Fitbit Charge HR 2, and electrocardiogram across different exercise intensities. J Sports Sci. 2019 Jun;37(12):1411-1419. doi: 10.1080/02640414.2018.1560644. Epub 2019 Jan 18. — View Citation
* Note: There are 21 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Specimen and data storage | To collect and store biological specimens (such as, but not limited to, tissue, blood, urine, cerebrospinal fluid, etc.), data from functional and anatomical imaging modalities, digital health data and clinical data from patients with cancer or neurological disorders, those who are under evaluation for a possible cancer or neurologic disorders, or healthy controls. | 4 years | |
Secondary | Specimen and data analysis | To perform multi-modality analysis of specimens for biomarker discovery. | 4 years | |
Secondary | Collaboration | To make specimens and data available to collaborating investigators performing IRB-approved research of cancer or neurological disorders. | 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05023434 -
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
|
||
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Completed |
NCT04114786 -
3D Printed Mask for GBM and Brain Mets
|
N/A | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Completed |
NCT02852655 -
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
|
Phase 1 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Completed |
NCT01650922 -
Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples
|
N/A | |
Completed |
NCT00329589 -
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
|
Phase 1 | |
Completed |
NCT00505141 -
Urban Environmental Exposures and Childhood Cancer
|
N/A | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Completed |
NCT00979810 -
Image-Guided Stereotactic Biopsy of High Grade Gliomas
|
N/A | |
Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
Active, not recruiting |
NCT02851706 -
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
|
||
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Completed |
NCT01012609 -
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
|
Phase 2 | |
Completed |
NCT00782756 -
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
|
Phase 2 | |
Terminated |
NCT03149575 -
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
|
Phase 3 | |
Completed |
NCT01974804 -
Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
|
||
Withdrawn |
NCT01320787 -
18-F-Fluoroacetate as PET Imaging Agent
|
Phase 1 |